NEW YORK (GenomeWeb) – Foundation Medicine said today that it is collaborating with the European Organisation for Research and Treatment of Cancer (EORTC) to provide cancer genomic profiling tests to help determine eligibility of patients for clinical trials.
Under the agreement, Foundation Medicine will provide testing services for EORTC's Screening Patients for Efficient Clinical Trial Access (SPECTA) program using its three genomic profiling assays: FoundationOne, FoundationOne Heme, and FoundationAct. The company will process the samples at any of its laboratories in the US and in Europe. Test results will help inform patient eligibility for clinical trials and facilitate their enrollment.
EORTC, an independent non-profit organization that is headquartered in Brussels, brings together more than 4,000 collaborators from all disciplines of cancer treatment and research at more than 800 hospitals and institutions in over 35 countries. SPECTA, its pan-European network, helps to provide patients access to molecularly driven clinical trials.
"Together, Foundation Medicine and the EORTC can work toward improved access to innovative clinical trials, helping to accelerate precision oncology for more patients," Foundation Medicine Chief Medical Officer Vincent Miller in a statement.
"Our collaboration with Foundation Medicine will provide access to innovative, biomarker-driven clinical trials that will ultimately usher in a new era of targeted therapy in oncology," said EORTC Director General Denis Lacombe in the same statement.